CoChat

Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer

Open access
Crown, John P., Diéras, Véronique, Staroslawska, Elzbieta, Yardley, Denise A., Bachelot, Thomas, Davidson, Neville, Wildiers, Hans, Fasching, Peter A., Capitain, Olivier, Ramos, Manuel, Greil, Richard, Cognetti, Francesco, Fountzilas, George, Blasinska-Morawiec, Maria, Liedtke, Cornelia, Kreienberg, Rolf, Miller, Wilson H., Tassell, Vanessa, Huang, Xin, Paolini, Jolanda, Kern, Kenneth A., Romieu, Gilles · 2013 · Journal of Clinical Oncology
Cited by 151

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Purpose: Metastatic breast cancer (MBC) remains an incurable illness in the majority of cases, despite major therapeutic advances. This may be related to the ability of breast tumors to induce neoangiogenesis, even in the face of cytotoxic chemotherapy. Sunitinib, an inhibitor of key molecules involved in neoangiogenesis, has an established role in the treatment of metastatic renal cell and other cancers and demonstrated activity in a phase II trial in MBC. We performed a randomized phase III trial comparing sunitinib plus capecitabine (2,000 mg/m 2 ) with single-agent capecitabine (2,500 mg/m 2 ) in patients with heavily pretreated MBC. Patients and Methods: Eligibility criteria included MBC, prior therapy with anthracyclines and taxanes, one or two prior chemotherapy regimens for metastatic disease or early relapse after a taxane plus anthracycline adjuvant regimen, and adequate organ function and performance status. The primary end point was progression-free survival, for which the study had 90% power to detect a 50% improvement (from 4 to 6 months). Results: A total of 442 patients were randomly assigned. Progression-free survival was not significantly different between the treatment arms, with medians of 5.5 months (95% CI, 4.5 to 6.0) for the sunitinib plus capecitabine arm and 5.9 months (95% CI, 5.4 to 7.6) for the capecitabine monotherapy arm (hazard ratio, 1.22; 95% CI, 0.95 to 1.58; one-sided P = .941). There were no significant differences in response rate or overall survival. Toxicity, except for hand-foot syndrome, was more severe in the combination arm. Conclusion: The addition of sunitinib to capecitabine does not improve the clinical outcome of patients with MBC pretreated with anthracyclines and taxanes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2012.43.3391

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 151

Metadata

Authors
Crown, J. P., Diéras, V., Staroslawska, E., Yardley, D. A., Bachelot, T., Davidson, N., Wildiers, H., Fasching, P. A., Capitain, O., Ramos, M., Greil, R., Cognetti, F., Fountzilas, G., Blasinska-Morawiec, M., Liedtke, C., Kreienberg, R., Miller, W. H., Tassell, V., Huang, X., Paolini, J., Kern, K. A., & Romieu, G.
Venue
Journal of Clinical Oncology
Published
2013-08-10
Volume
31
Issue
23
Pages
2870-2878
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2132046158
Cited by
151
References
4
FWCI
11.86
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer. https://app.cochat.ai/papers/10.1200/jco.2012.43.3391
The paper
Crown, J. P., Diéras, V., Staroslawska, E., Yardley, D. A., Bachelot, T., Davidson, N., Wildiers, H., Fasching, P. A., Capitain, O., Ramos, M., Greil, R., Cognetti, F., Fountzilas, G., Blasinska-Morawiec, M., Liedtke, C., Kreienberg, R., Miller, W. H., Tassell, V., Huang, X., . . . Romieu, G. (2013). Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.43.3391

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.